


## Oxypertine

<b>Cat. No.:</b>	HY-119677
<b>CAS No.:</b>	153-87-7
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>29</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	379.5
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Oxypertine is a neuroprotective agent. Oxypertine can be used in the research of neurological conditions, such as anxiety and schizophrenia <sup>[1][2][3]</sup> .																
<b>In Vitro</b>	Oxypertine (0.44 nM-26 μM, 15 min) antagonizes dopamine and 5-HT induced contractions of the rat isolated vas deferens <sup>[1]</sup> . Oxypertine (8.8 nM, 15 min) reduces the contractions evoked by transmural stimulation of the vas deferens <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>Oxypertine (10 and 35 mg/kg, i.p.) causes an obvious dose-related depletion in the levels of norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) in various discrete regions of the rat brain<sup>[2]</sup>.</p> <p>Oxypertine (0.625-20 mg/kg, i.p.) inhibits stereotyped behaviour induced by both amphetamine and apomorphine in rats<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice with chronic restraint stress<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 35 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.)</td> </tr> <tr> <td>Result:</td> <td>Increased the level of homovanillic acid in three discrete regions, i.e., the cortex, striatum and mid-brain. Inhibited Apomorphine-induced stereotypy.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice with stereotyped behaviour induced by amphetamine (5.0 mg/kg i.p.) and apomorphine (1.0 mg/kg, s.c.)<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.625-20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.)</td> </tr> <tr> <td>Result:</td> <td>Reduced the content of dopamine in the striatum but increased the concentrations of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC).</td> </tr> </table>	Animal Model:	Mice with chronic restraint stress <sup>[2]</sup>	Dosage:	10, 35 mg/kg	Administration:	Intraperitoneal injection (i.p.)	Result:	Increased the level of homovanillic acid in three discrete regions, i.e., the cortex, striatum and mid-brain. Inhibited Apomorphine-induced stereotypy.	Animal Model:	Mice with stereotyped behaviour induced by amphetamine (5.0 mg/kg i.p.) and apomorphine (1.0 mg/kg, s.c.) <sup>[3]</sup>	Dosage:	0.625-20 mg/kg	Administration:	Intraperitoneal injection (i.p.)	Result:	Reduced the content of dopamine in the striatum but increased the concentrations of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC).
Animal Model:	Mice with chronic restraint stress <sup>[2]</sup>																
Dosage:	10, 35 mg/kg																
Administration:	Intraperitoneal injection (i.p.)																
Result:	Increased the level of homovanillic acid in three discrete regions, i.e., the cortex, striatum and mid-brain. Inhibited Apomorphine-induced stereotypy.																
Animal Model:	Mice with stereotyped behaviour induced by amphetamine (5.0 mg/kg i.p.) and apomorphine (1.0 mg/kg, s.c.) <sup>[3]</sup>																
Dosage:	0.625-20 mg/kg																
Administration:	Intraperitoneal injection (i.p.)																
Result:	Reduced the content of dopamine in the striatum but increased the concentrations of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC).																

---

## REFERENCES

---

- [1]. H Miranda, et al. Effects of oxypertine on the isolated vas deferens of the rat. *Br J Pharmacol.* 1978 Apr;62(4):515-8.
- [2]. T Moroji, et al. Neurochemical and behavioral studies on the mode of action of oxypertine. *Arzneimittelforschung.* 1986 May;36(5):804-8.
- [3]. M Hong, et al. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA